Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JMT101 + SG001 + irinotecan
- Development stage
- Unknown
- Lead developer
- Shanghai Jinmante Biotechnology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
JMT101 + SG001 + irinotecan is a triple combination therapy studied for metastatic colorectal adenocarcinoma (mCRC) in resistant, RAS/BRAF-wild-type, non-MSI-H/dMMR patients. JMT101 is a humanized monoclonal IgG1 antibody targeting epidermal growth factor receptor (EGFR), inhibiting EGFR-mediated cellular proliferation. SG001 is a fully humanized IgG4 monoclonal antibody targeting programmed death-1 (PD-1), functioning as a checkpoint inhibitor to enhance antitumor immune responses. Irinotecan is a small molecule chemotherapeutic agent, a DNA topoisomerase I inhibitor, which interferes with DNA replication and transcription, causing S-G2 phase arrest and cell death. This combination leverages synergistic cancer cell killing via direct cytotoxicity (irinotecan), EGFR blockade (JMT101), and immunomodulation (SG001), aiming to improve response in refractory mCRC[1][3][5][6][7].
- Brand names
- Onivyde Pegylated Liposomal
- Other names
- BecotatugEnlonstobart
02
Targets
TOP1 (DNA Topoisomerase I)EGFR (Epidermal growth factor receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on JMT101 + SG001 + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JMT101 + SG001 + irinotecan.